Afimmune announces DS102 will be developed for pulmonary disorders in addition to NASH

Afimmune presents late-breaking news abstract on DS102 at the European Association for the Study of the Liver (EASL) International Liver Congress
April 14, 2016
Afimmune’s DS102 receives FDA fast track designation as an investigational treatment for patients suffering from NASH with liver fibrosis
March 29, 2017
Show all

Afimmune announces DS102 will be developed for pulmonary disorders in addition to NASH

Dublin, Ireland, 23rd May, 2016: Afimmune today announced plans to develop its anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive pulmonary disease (COPD) patients as well as in non-alcoholic steatohepatitis (NASH) patients.

Recent Afimmune preclinical data suggests that DS102 is significantly sequestered in lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties in the same tissue after oral administration. The Company will publish further detail on these findings later in the year.

In view of this, the Company is planning a Phase IIa clinical trial in COPD patients and will start a Phase IIa study with DS102 in NASH patients later this year.

Afimmune CEO, Dr. John Climax, said: ‘The additional positive preclinical data supports the anti-fibrotic and anti-inflammatory mechanisms previously observed with DS102 in murine models for NASH. The Company is very encouraged by the potential utility of DS102 both in NASH and in pulmonary disorders such as COPD and IPF.’

About Afimmune

Afimmune Limited (Afimmune), headquartered in Dublin, Ireland, is a drug discovery and development company working on inflammatory conditions of the human primary organs including the liver and the lung.

Afimmune: [email protected]

Updated from DS Biopharma to Afimmune as effective from 22nd August 2016